The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase II
9543: A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients with Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL). MD Anderson Cancer Center; Burger, Jan A. (713) 792-1865
AMC-089: A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients with AIDS-Associated Kaposi Sarcoma. AIDS-Associated Malignancies Clinical Trials Consortium; Ratner, Lee. (314) 362-8836
CITN-07-FLT3L: A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. Cancer Immunotherapy Trials Network; Bhardwaj, Nina. (212) 263-5814
Phase Other
AALL14B1-Q: Deep Sequencing for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia ALL. Children’s Oncology Group; Wood, Brent Lee. (206) 288-7115
AAML14B4-Q: Role of EVI-1 Hyperexpression in Pediatric and Young Adult Acute Myeloid Leukemia. Children’s Oncology Group; Qian, Zhijian. (312) 355-3295
EA914LT1: Lab Testing of AML Patient Samples. ECOG-ACRIN Cancer Research Group; Wald, David. (216) 368-5668
S0016B: Use of Chromosome Genomic Microarray Testing (CGAT) to Identify Novel Genetic Aberrations Impacting Patient Outcome in S0016 Follicular Lymphoma Patients. SWOG; Fang, Min (206) 288-1385
Pilot Phase
ABTC-1301: Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients. Adult Brain Tumor Consortium; Lee, Eudocia Quant. (617) 632-2166
